Tesaro slips on slow Zejula uptake

Tesaro Inc. (NASDAQ:TSRO) lost $13.64 (12%) to $98.44 on Wednesday after reporting lighter-than-expected 3Q sales for ovarian cancer drug Zejula niraparib. Tesaro released its earnings after market hours on Tuesday.

The company posted Zejula revenues of $39.4 million, just missing the consensus estimate of $42 million. FDA approved Zejula in March as maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer in patients who are in complete or partial response to platinum-based chemotherapy. The company plans to launch the oral poly(ADP-ribose) polymerase (PARP) inhibitor in Europe by year end...